What is the Fiscal Year for Lyell Immunopharma?

Headquarters

South San Francisco, CA

Industry

Biotechnology Research

Stock Symbol

LYEL

Website

Description

Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. We have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission's urgency.